Solid Biosciences Receives Rare Pediatric Disease Designation for SGT-212 Gene Therapy for Friedreich’s Ataxia
Tuesday, December 02, 2025
Solid Biosciences has received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, its investigational gene therapy being developed for Friedreich’s ataxia (FA).
SGT-212 is a recombinant AAV-based gene replacement therapy designed to deliver the full-length human frataxin gene. It is administered through targeted IDN infusion using an FDA-approved, MRI-guided device, followed by an IV infusion to increase frataxin levels in both the cerebellar dentate nuclei and cardiomyocytes. The IDN delivery is monitored in real time using gadolinium contrast. Restoring frataxin levels aims to correct mitochondrial dysfunction and improve neurological and cardiac symptoms associated with FA.
Friedreich’s ataxia is an inherited, progressive condition caused by defects in the frataxin gene, which reduce production of a mitochondrial protein essential for energy generation. The disease leads to severe neurological problems, movement difficulties and cardiac impairment, with heart complications being the leading cause of death. FA affects about 5,000 people in the United States and around 15,000 in Europe. There are currently no approved treatments that cure or stop disease progression.
The therapy uses a dual route of administration, combining direct intradentate nucleus (IDN) delivery with an intravenous (IV) infusion, to restore functional levels of the frataxin protein. This approach aims to address the neurological, cardiac and systemic complications linked to FA.
The Rare Pediatric Disease designation supports the development of treatments for serious conditions affecting patients under 18 years of age. This designation may allow the company to obtain a Priority Review Voucher, which can accelerate future regulatory reviews and may be used, transferred or sold.
The company noted that the new designation, together with the previously granted Fast Track status, highlights the importance of its dual-route clinical strategy in the ongoing FALCON first-in-human trial. The study is currently screening participants.
Source: solidbio.com
